Purpose The platinum chemotherapy agents cisplatin and carboplatin are widely used in
the treatment of adult and pediatric cancers. Cisplatin causes hearing loss in at least 60% of …

Anthracyclines are used in over 50% of childhood cancer treatment protocols 1 , but their
clinical usefulness is limited by anthracycline-induced cardiotoxicity (ACT) manifesting as …

Aims Anthracycline‐induced cardiotoxicity (ACT) occurs in 57% of treated patients and
remains an important limitation of anthracycline‐based chemotherapy. In various genetic …

Background Cisplatin is used to treat a wide range of childhood cancers and cisplatin-induced
hearing loss (CIHL) is a common and debilitating toxicity. We aimed to address persistent …

Objectives: The objective of this study was to determine treatment outcomes and long-term
complications in pediatric patients with Ewing Sarcoma treated at the British Columbia …

Vincristine is an effective chemotherapeutic drug for various cancers, including acute
lymphoblastic leukemia ( ALL ). Unfortunately, clinical utility is restricted by dose‐limiting vincristine…

Poorly differentiated chordoma (PDC) is a recently recognized subtype of chordoma characterized
by expression of the embryonic transcription factor, brachyury, and loss of INI1. PDC …

Currently no pharmacogenomics-based criteria exist to guide clinicians in identifying
individuals who are at risk of hearing loss from cisplatin-based chemotherapy. This review …

Purpose: Cisplatin-induced hearing loss (CIHL) is common and permanent. As compared
with earlier otoprotectants, we hypothesized N-acetylcysteine (NAC) offers potential for …

Background Although survivors of childhood, adolescent, and young adult (AYA) cancer are
at risk for late psychological sequelae, it is unclear if they are more likely to be prescription …